Description
Mubritinib is an EGFR2 (HER2) inhibitor that underwent clinical trials, showing some promise as an anticancer chemotherapeutic in the treatment of bladder, kidney, and prostate cancer, but was not pursued further.
Product Unit Size | Cost | Quantity | Stock |
---|
Mubritinib is an EGFR2 (HER2) inhibitor that underwent clinical trials, showing some promise as an anticancer chemotherapeutic in the treatment of bladder, kidney, and prostate cancer, but was not pursued further.
Cas No. | 366017-09-6 |
---|---|
Purity | ≥99% |
Formula | C25H23F3N4O2 |
Formula Wt. | 468.47 |
Chemical Name | 1-(4-{4-[(2-{(E)-2-[4-(trifluoromethyl)phenyl]ethenyl}-1,3-oxazol-4-yl)methoxy]phenyl}butyl)-1H-1,2,3-triazole |
IUPAC Name | 4-[[4-[4-(triazol-1-yl)butyl]phenoxy]methyl]-2-[(E)-2-[4- (trifluoromethyl)phenyl]ethenyl]-1,3-oxazole |
Synonym | TAK-165 |
Appearance | White to off white powder |
Store Temp | Ambient |
---|---|
Ship Temp | Ambient |
MSDS | |
---|---|
Info Sheet |
Nagasawa J, Mizokami A, Koshida K, et al. Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo. Int J Urol. 2006 May;13(5):587-92. PMID: 16771730.
Cephalomannine derivative found in Taxus; poten...
Long chain acylcarnitine involved in fatty acid...
GHS-R1a agonist, γ-secretase inhibitor.
Peptide, c-Kit ligand fragment.
Fluoroquinolone; topoisomerase IV, topoisomeras...
Thrombin substrate used to measure thrombin act...
Kavalactone originally found in Piper methystic...
Endogenous peptide, cleavage product of AT II; ...
Glycylcycline; protein synthesis inhibitor.
Potential ATP-sensitive K+ channel blocker, pot...
c-MET inhibitor.
Bisphosphonate.
Inhibitor of Akt.
Intermediate in the synthesis of purine analogs...
AT1 inhibitor.
Synthetic peptide fragment, prion protein analo...
Mycotoxin produced by species of Aspergillus; D...
Dihydrofolate reductase inhibitor.
Derivative of methyl caffeate, hydroxycinnamic ...
Piperazine; FIASMA, D2 antagonist, hERG K+ chan...